PMID- 20135347
OWN - NLM
STAT- MEDLINE
DCOM- 20100616
LR  - 20220316
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 120
IP  - 2
DP  - 2010 Apr
TI  - Epidermal growth factor receptor and vascular endothelial growth factor receptor 
      2 are specific biomarkers in triple-negative breast cancer. Results from a 
      controlled randomized trial with long-term follow-up.
PG  - 491-8
LID - 10.1007/s10549-010-0758-6 [doi]
AB  - Triple-negative breast cancer (TNB) has poor prognosis and moreover patients with 
      TNB do not benefit from established targeted drugs with endocrine therapy or 
      trastuzumab. The aim of the study was to analyze the prevalence of candidate 
      biomarkers in tumors from patients with TNB. Tissue microarrays were prepared 
      from primary tumors from premenopausal breast cancer patients (500/564) 
      randomized to adjuvant tamoxifen or no adjuvant treatment. Immunohistochemical 
      (IHC) staining included ER, PR, HER2, epidermal receptor growth factor (EGFR), 
      vascular endothelial growth factor A (VEGF-A), and vascular endothelial growth 
      factor receptor 2 (VEGFR2). EGFR and HER2 gene copy number was defined by 
      fluorescence in situ hybridization (FISH). All patients were included in the 
      descriptive analysis, but only untreated patients in the survival analysis. TNB 
      was diagnosed in 96 patients and correlated significantly to low age, Nottingham 
      histological grade (NHG) III, high Ki67-index, T2 tumors, node negativity, EGFR 
      positivity, increased EGFR gene copy number and high VEGFR2 expression. TNB was 
      an independent prognostic factor for decreased 5-year breast cancer specific 
      survival (BCSS) (HR 2.0 (95% CI 1.1-3.6), P = 0.01), but not for 10-year BCSS. 
      High VEGFR2 expression was significantly correlated to decreased BCSS in TNB 
      patients. TNB was associated with decreased BCSS and clinicopathological 
      characteristics of an aggressive tumor type. High VEGFR2 expression, EGFR 
      expression, and EGFR gene copy number were significantly correlated to TNB, 
      supporting their role as putative candidate biomarkers for selection of targeted 
      therapy in TNB.
FAU - Ryden, Lisa
AU  - Ryden L
AD  - Department of Surgery, Institution of Clinical Sciences, Lund University 
      Hospital, SE 221 85, Lund, Sweden. Lisa.Ryden@med.lu.se
FAU - Jirstrom, Karin
AU  - Jirstrom K
FAU - Haglund, Monica
AU  - Haglund M
FAU - Stal, Olle
AU  - Stal O
FAU - Ferno, Marten
AU  - Ferno M
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100205
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Biomarkers, Tumor/*genetics
MH  - Breast Neoplasms/drug therapy/*genetics/metabolism
MH  - Chemotherapy, Adjuvant
MH  - ErbB Receptors/biosynthesis/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Dosage
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Receptor, ErbB-2/biosynthesis/genetics
MH  - Receptors, Estrogen/biosynthesis/genetics
MH  - Receptors, Progesterone/biosynthesis/genetics
MH  - Tamoxifen/therapeutic use
MH  - Tissue Array Analysis
MH  - Vascular Endothelial Growth Factor Receptor-2/biosynthesis/*genetics
EDAT- 2010/02/06 06:00
MHDA- 2010/06/17 06:00
CRDT- 2010/02/06 06:00
PHST- 2009/10/08 00:00 [received]
PHST- 2010/01/19 00:00 [accepted]
PHST- 2010/02/06 06:00 [entrez]
PHST- 2010/02/06 06:00 [pubmed]
PHST- 2010/06/17 06:00 [medline]
AID - 10.1007/s10549-010-0758-6 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2010 Apr;120(2):491-8. doi: 10.1007/s10549-010-0758-6. 
      Epub 2010 Feb 5.